GSK scandal aftermath leads to a rise of beefed up internal controls
By Shannon Ellis
Wednesday, August 13, 2014
HONG KONG It's been more than a year since Chinese authorities leveled allegations against Glaxosmithkline plc (GSK) for corrupt activities amounting to almost $500 million in bribes, setting off an industrywide crackdown that has garnered the attention of not only the Chinese, but also the U.S. and UK anti-corruption authorities.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.